These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy. Augsburger JJ; Corrêa ZM; Trichopoulos N Arq Bras Oftalmol; 2013; 76(2):72-9. PubMed ID: 23828465 [TBL] [Abstract][Full Text] [Related]
3. Comparison of uveal melanoma cytopathologic sample retrieval in trans-scleral versus vitrectomy-assisted transvitreal fine needle aspiration biopsy. Chang MY; McCannel TA Br J Ophthalmol; 2014 Dec; 98(12):1654-8. PubMed ID: 24997179 [TBL] [Abstract][Full Text] [Related]
4. Uveal melanoma radiation. 125I brachytherapy versus helium ion irradiation. Char DH; Castro JR; Quivey JM; Phillips TL; Irvine AR; Stone RD; Kroll S Ophthalmology; 1989 Dec; 96(12):1708-15. PubMed ID: 2695875 [TBL] [Abstract][Full Text] [Related]
5. Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Harbour JW; Char DH; Kroll S; Quivey JM; Castro J Ophthalmology; 1997 Nov; 104(11):1785-92; discussion 1792-3. PubMed ID: 9373108 [TBL] [Abstract][Full Text] [Related]
6. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534 [TBL] [Abstract][Full Text] [Related]
7. Scleral necrosis in patients with posterior uveal melanomas evaluated by transcleral fine needle aspiration biopsy and treated by 125I plaque. Correa ZM; Huth B; Augsburger JJ Arq Bras Oftalmol; 2018; 81(4):330-335. PubMed ID: 29995126 [TBL] [Abstract][Full Text] [Related]
8. Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit. Sánchez-Tabernero S; García-Alvarez C; Muñoz-Moreno MF; Diezhandino P; Alonso-Martínez P; de Frutos-Baraja JM; López-Lara F; Saornil MA Am J Ophthalmol; 2017 Aug; 180():39-45. PubMed ID: 28572063 [TBL] [Abstract][Full Text] [Related]
16. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966 [TBL] [Abstract][Full Text] [Related]
17. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Quivey JM; Augsburger J; Snelling L; Brady LW Cancer; 1996 Jun; 77(11):2356-62. PubMed ID: 8635107 [TBL] [Abstract][Full Text] [Related]
18. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Kroll S; Char DH; Quivey J; Castro J Ophthalmology; 1998 Nov; 105(11):2035-45. PubMed ID: 9818602 [TBL] [Abstract][Full Text] [Related]
19. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Toivonen P; Kivelä T Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837 [TBL] [Abstract][Full Text] [Related]
20. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]